Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage
| Autor: | Stefanie Gilchrist, Morena Lo Sapio, Jay Lucidarme, Giacomo Frosi, Ray Borrow, Mariagrazia Pizza, Duccio Medini, Jamie Findlow, Marzia Monica Giuliani, Alessia Biolchi, Fabio Rigat |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Meningococcal Vaccines Biology Neisseria meningitidis Serogroup B Serum Bactericidal Antibody Assay medicine.disease_cause Stratified proportional sampling Group B 4CMenB vaccine strain coverage Predictive Value of Tests Immunology and Microbiology(all) Epidemiology medicine Humans Typing Child Antigens Bacterial Wales General Veterinary General Immunology and Microbiology Strain (chemistry) Neisseria meningitidis Vaccination Public Health Environmental and Occupational Health Infant MATS Virology veterinary(all) Antibodies Bacterial Healthy Volunteers Meningococcal Infections Infectious Diseases England Child Preschool Immunology Multilocus sequence typing Molecular Medicine Female Neisseria meningitidis serogroup B |
| Zdroj: | Vaccine. 31(43) |
| ISSN: | 1873-2518 |
| Popis: | Background 4CMenB (Bexsero), a vaccine developed against invasive meningococcal disease caused by capsular group B strains (MenB), was recently licensed for use by the European Medicines Agency. Assessment of 4CMenB strain coverage in specific epidemiologic settings is of primary importance to predict vaccination impact on the burden of disease. The Meningococcal Antigen Typing System (MATS) was developed to predict 4CMenB strain coverage, using serum bactericidal antibody assay with human complement (hSBA) data from a diverse panel of strains not representative of any specific epidemiology. Objective To experimentally validate the accuracy of MATS-based predictions against strains representative of a specific epidemiologic setting. Methods and results We used a stratified sampling method to identify a representative sample from all MenB disease isolates collected from England and Wales in 2007–2008, tested the strains in the hSBA assay with pooled sera from infant and adolescent vaccinees, and compared these results with MATS. MATS predictions and hSBA results were significantly associated ( P = 0.022). MATS predicted coverage of 70% (95% CI, 55–85%) was largely confirmed by 88% killing in the hSBA (95% CI, 72–95%). MATS had 78% accuracy and 96% positive predictive value against hSBA. Conclusion MATS is a conservative predictor of strain coverage by the 4CMenB vaccine in infants and adolescents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect